Chardan Capital Reaffirms Buy Rating for Solid Biosciences (NASDAQ:SLDB)
Solid Biosciences (NASDAQ:SLDB – Get Free Report)‘s stock had its “buy” rating reaffirmed by stock analysts at Chardan Capital in a research note issued on Friday,Benzinga reports. They presently have a $16.00 price objective on the stock. Chardan Capital’s target price indicates a potential upside of 195.20% from the stock’s current price. A number of […]
Solid Biosciences (NASDAQ:SLDB – Get Free Report)‘s stock had its “buy” rating reaffirmed by stock analysts at Chardan Capital in a research note issued on Friday,Benzinga reports. They presently have a $16.00 price objective on the stock. Chardan Capital’s target price indicates a potential upside of 195.20% from the stock’s current price. A number of […]
